Gouging Cystinuria Patients (And Others) - No Surprise Here.

"In September, a tiny biotech called Retrophin bought a drug for a rare kidney condition called cystinuria and raised the price from $1.50 per pill to $30 per pill. The company’s chief executive, a 31-year-old investor named Martin Shkreli, argued that the higher price would lead to greater access for patients, and that nobody would be denied. 'No patient will be left behind, over my dead body,' Shkreli wrote on Reddit, as he defended the decision. 'No one will be forced to pay exorbitant amounts for their drug. We give you the drug and figure it out with your insurer.'"

http://www.forbes.com/sites/matthewherper/2014/10/14/a-drug-regrew-a-little-girls-missing-bones-how-much-should-that-cost/